Egypt

The Egyptian Drug Authority (EDA), established under Law No. 151 of 2019 as a replacement for the Egyptian Drug Authority's predecessor bodies, serves as the primary national regulatory authority overseeing pharmaceuticals, medical devices, diagnostics, and related health products in Egypt. The EDA operates under the broad legislative framework of Law No. 127 of 1955 on the Practice of Pharmacy and its subsequent amendments, alongside specific regulations governing medical devices and in-vitro diagnostics. The general approval process requires manufacturers or their local representatives to submit a registration dossier to the relevant EDA department, followed by technical review, quality assessment, and in some cases local laboratory testing or facility inspection before a marketing authorization is granted.

All foreign manufacturers seeking registration in Egypt must appoint a locally registered agent or representative, who assumes legal responsibility for the product within the Egyptian market. The EDA accepts dossiers largely aligned with the Common Technical Document (CTD) format, and applications referencing approvals from stringent regulatory authorities such as the US FDA, EMA, or Health Canada may benefit from expedited or abridged review pathways. In recent years, Egypt has undertaken significant regulatory reforms aimed at modernizing the registration system, including the digitization of submission portals, the introduction of risk-based classification frameworks for medical devices, and efforts to harmonize standards with international guidelines. The EDA has also introduced priority review tracks for products addressing unmet medical needs and has expanded post-market surveillance requirements to align with global best practices.

Public procurement of health products in Egypt is primarily centralized through the Ministry of Health and Population (MoHP), which coordinates national tender processes for pharmaceuticals, medical devices, diagnostics, and other health commodities. The Central Administration for Pharmaceutical Affairs (CAPA), operating under the MoHP, plays a key role in managing drug procurement and pricing decisions for the public sector. Large-scale government tenders are governed by the Public Procurement Law No. 182 of 2018, which introduced greater transparency and competitive bidding requirements. The Egyptian Health Insurance Authority (under the Universal Health Insurance Law No. 2 of 2018) is increasingly becoming a significant procurement entity as Egypt rolls out its Universal Health Coverage (UHC) scheme across governorates, with Sinai serving as the initial pilot region. Procurement decisions at the public level often factor in local manufacturing preferences, price controls, and registered product status with the EDA.

Beyond the public sector, Egypt has a substantial private market that operates through a network of private distributors, hospital chains, and retail pharmacies, representing a significant share of overall health product consumption. International and donor-funded procurement channels also play a role, particularly for public health programs targeting infectious diseases, maternal and child health, and vaccination campaigns. Organizations such as UNICEF, the World Health Organization (WHO), the Global Fund to Fight AIDS, Tuberculosis and Malaria, and USAID have historically supported procurement of specific health commodities in Egypt, often requiring products to meet international prequalification standards such as WHO Prequalification or equivalent stringent regulatory authority approval. Egypt's government has placed increasing emphasis on local manufacturing as a strategic priority, incentivizing domestic production through preferential pricing margins in public tenders and partnerships with multinational companies to establish local manufacturing or technology transfer arrangements.